


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the September 2013 NCCN Trends™ Survey, which focused on Mantle Cell Lymphoma. This survey was sent to U.S. and International users of NCCN.org.


DEMOGRAPHICS

Distribution of Respondent Types (n = 726)




Note: Percentages may not total 100 because of rounding.

Q1. Do you treat patients with mantle cell lymphoma? (n = 650)




Q2. When using bortezomib for your patients with mantle cell lymphoma, which route of administration do you use? (n = 322)



Q2. When using bortezomib for your patients with mantle cell lymphoma, which route of administration do you use?

By Geography


- Intravenous
- Subcutaneous
- I don't use bortezomib with mantle cell lymphoma



Q2. When using bortezomib for your patients with mantle cell lymphoma, which route of administration do you use?


By Practice Size

- Intravenous
- Subcutaneous
- I don't use bortezomib with mantle cell lymphoma



Q2. When using bortezomib for your patients with mantle cell lymphoma, which route of administration do you use?


By Practice Setting




Q2. When using bortezomib for your patients with mantle cell lymphoma, which route of administration do you use?

By Specialty

- Intravenous
- Subcutaneous
- I don't use bortezomib with mantle cell lymphoma




Q3. When using bortezomib for your relapsed mantle cell lymphoma patients, please indicate how you typically give it. (n = 204)




Q3. When using bortezomib for your relapsed mantle cell lymphoma patients, please indicate how you typically give it.

By Geography




Q3. When using bortezomib for your relapsed mantle cell lymphoma patients, please indicate how you typically give it.



Q3. When using bortezomib for your relapsed mantle cell lymphoma patients, please indicate how you typically give it.

By Practice Setting


- As a single agent
- In combination with other agents




Q3. When using bortezomib for your relapsed mantle cell lymphoma patients, please indicate how you typically give it.

By Specialty

- As a single agent
- In combination with other agents




Q4. For patients receiving bortezomib in second line, what was their first line treatment regimen? (Please select all that apply) (n = 206)



Q4. For patients receiving bortezomib in second line, what was their first line treatment regimen? (Please select all that apply)



By Geography

- US Midwest
- US Northeast
- US South
- US West
- Europe
- Latin America
- Asia
- Other Non-US



Q4. For patients receiving bortezomib in second line, what was their first line treatment regimen? (Please select all that apply)


By Practice Size



Q4. For patients receiving bortezomib in second line, what was their first line treatment regimen? (Please select all that apply)

By Practice Setting


■ Academic Setting
■ Community Setting



Q4. For patients receiving bortezomib in second line, what was their first line treatment regimen? (Please select all that apply)


By Specialty

- Medical Oncology
- Radiation Oncology
- Surgical Oncology
- Internal Medicine
- General Surgery
- Other



Q5. Lenalidomide is indicated for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

In which line of therapy do you typically consider lenalidomide? (Please select one response) (n = 303)




Q5. Lenalidomide is indicated for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

In which line of therapy do you typically consider lenalidomide? (Please select one response)

By Geography


- 1st line
- 2nd line
- 3rd line or beyond
- I don't use lenalidomide for mantle cell lymphoma



Q5. Lenalidomide is indicated for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

In which line of therapy do you typically consider lenalidomide? (Please select one response)


By Practice Size



Q5. Lenalidomide is indicated for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

In which line of therapy do you typically consider lenalidomide? (Please select one response)



By Practice Setting



Q5. Lenalidomide is indicated for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

In which line of therapy do you typically consider lenalidomide? (Please select one response)

By Specialty



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.org/patients - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.